Opinion: What defines high-risk CLL in the
post-chemoimmunotherapy era?

J 2023

Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

EDELMANN, Jennifer; Jitka MALČÍKOVÁ a John C RICHES

Základní údaje

Originální název

Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

Autoři

EDELMANN, Jennifer; Jitka MALČÍKOVÁ a John C RICHES

Vydání

Frontiers in Oncology, Lausanne, Frontiers Media S.A. 2023, 2234-943X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.500

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/23:00131063

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

chronic lymphocytic leukemia (CLL); high-risk; TP53; definition; BTK - Bruton's tyrosine kinase; BCL2 (B-cell lymphoma 2); COVID-19; risk factor

Štítky

podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 3. 2024 08:20, Mgr. Tereza Miškechová

Anotace

V originále

The definition of high-risk chronic lymphocytic leukemia (CLL) was relatively simple in the chemoimmunotherapy era, as it was defined by only one genomic marker, TP53 alteration, along with poor responses to purine-analogue based treatment. While other biomarkers such as unmutated IGHV, del(11q), high ZAP70 expression and high CD38 expression were associated with inferior prognosis, TP53 deficiency by mutation and/or del(17p) remained the only biomarker that clearly guided treatment decisions.

Návaznosti

LX22NPO5102, projekt VaV

Název: Národní ústav pro výzkum rakoviny (Akronym: NÚVR)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Národní ústav pro výzkum rakoviny, 5.1 EXCELES

Přiložené soubory

Opinion_What_defines_high-risk_CLL_in_the_post-chemoimmunotherapy_era.pdf

Citovat

EDELMANN, Jennifer; Jitka MALČÍKOVÁ a John C RICHES. Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era? Frontiers in Oncology. Lausanne: Frontiers Media S.A., 2023, roč. 13, February 2023, s. 1-5. ISSN 2234-943X. Dostupné z: https://doi.org/10.3389/fonc.2023.1106579.

@article{2293252,
   author = {Edelmann, Jennifer and Malčíková, Jitka and Riches, John C},
   article_location = {Lausanne},
   article_number = {February 2023},
   doi = {https://doi.org/10.3389/fonc.2023.1106579},
   keywords = {chronic lymphocytic leukemia (CLL); high-risk; TP53; definition; BTK - Bruton's tyrosine kinase; BCL2 (B-cell lymphoma 2); COVID-19; risk factor},
   language = {eng},
   issn = {2234-943X},
   journal = {Frontiers in Oncology},
   title = {Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?},
   url = {https://www.frontiersin.org/articles/10.3389/fonc.2023.1106579/full},
   volume = {13},
   year = {2023}
}

TY  - JOUR
ID  - 2293252
AU  - Edelmann, Jennifer - Malčíková, Jitka - Riches, John C
PY  - 2023
TI  - Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?
JF  - Frontiers in Oncology
VL  - 13
IS  - February 2023
SP  - 1-5
EP  - 1-5
PB  - Frontiers Media S.A.
SN  - 2234943X
KW  - chronic lymphocytic leukemia (CLL)
KW  - high-risk
KW  - TP53
KW  - definition
KW  - BTK - Bruton's tyrosine kinase
KW  - BCL2 (B-cell lymphoma 2)
KW  - COVID-19
KW  - risk factor
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2023.1106579/full
N2  - The definition of high-risk chronic lymphocytic leukemia (CLL) was relatively simple in the chemoimmunotherapy era, as it was defined by only one genomic marker, TP53 alteration, along with poor responses to purine-analogue based treatment. While other biomarkers such as unmutated IGHV, del(11q), high ZAP70 expression and high CD38 expression were associated with inferior prognosis, TP53 deficiency by mutation and/or del(17p) remained the only biomarker that clearly guided treatment decisions.
ER  -

EDELMANN, Jennifer; Jitka MALČÍKOVÁ a John C RICHES. Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era? \textit{Frontiers in Oncology}. Lausanne: Frontiers Media S.A., 2023, roč.~13, February 2023, s.~1-5. ISSN~2234-943X. Dostupné z: https://doi.org/10.3389/fonc.2023.1106579.

Přehled o publikaci